Format
Items per page
Sort by

Send to:

Choose Destination

Results: 42

1.

Moclobemide: therapeutic use and clinical studies.

Bonnet U.

CNS Drug Rev. 2003 Spring;9(1):97-140. Review.

PMID:
12595913
2.

Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.

Bonnet U.

CNS Drug Rev. 2002 Fall;8(3):283-308. Review.

PMID:
12353059
3.

[The serotoninergic syndrome: moclobemide and citalopram].

Gumà M, Clemente F, Segura A, Costa J.

Med Clin (Barc). 1999 Nov 20;113(17):677-8. Review. Spanish. No abstract available.

PMID:
10618787
4.

Moclobemide in patients with dementia and depression.

Amrein R, Martin JR, Cameron AM.

Adv Neurol. 1999;80:509-19. Review.

PMID:
10410765
5.
6.
7.

Moclobemide. An update of its pharmacological properties and therapeutic use.

Fulton B, Benfield P.

Drugs. 1996 Sep;52(3):450-74. Review. Erratum in: Drugs 1996 Dec;52(6):869.

PMID:
8875133
8.

Moclobemide in the treatment of social phobia.

Nutt D, Montgomery SA.

Int Clin Psychopharmacol. 1996 Jun;11 Suppl 3:77-82. Review.

PMID:
8923114
9.

Moclobemide: a paradigm of research in clinical psychopharmacology.

Angst J, Amrein R, Stabl M.

Int Clin Psychopharmacol. 1996 Jun;11 Suppl 3:3-7. Review.

PMID:
8923103
10.

Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Mayersohn M, Guentert TW.

Clin Pharmacokinet. 1995 Nov;29(5):292-332. Review.

PMID:
8582117
11.

Moclobemide safety: monitoring a newly developed product in the 1990s.

Hilton S, Jaber B, Ruch R.

J Clin Psychopharmacol. 1995 Aug;15(4 Suppl 2):76S-83S. Review.

PMID:
7593735
12.

A risk-benefit assessment of moclobemide in the treatment of depressive disorders.

Norman TR, Burrows GD.

Drug Saf. 1995 Jan;12(1):46-54. Review.

PMID:
7741983
13.

Moclobemide.

Freeman H.

Lancet. 1993 Dec 18-25;342(8886-8887):1528-32. Review. No abstract available.

PMID:
7902906
14.

Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.

Nair NP, Ahmed SK, Kin NM.

J Psychiatry Neurosci. 1993 Nov;18(5):214-25. Review.

15.

Clinical overview on moclobemide.

Tiller JW.

Prog Neuropsychopharmacol Biol Psychiatry. 1993 Sep;17(5):703-12. Review.

PMID:
8255982
16.

An update of recent moclobemide interaction data.

Dingemanse J.

Int Clin Psychopharmacol. 1993 Jan;7(3-4):167-80. Review.

PMID:
8468439
17.

The role of moclobemide in endogenous depression: a survey of recent data.

Woggon B.

Int Clin Psychopharmacol. 1993 Jan;7(3-4):137-9. Review.

PMID:
8468434
18.

Moclobemide--placebo-controlled trials.

Silverstone T.

Int Clin Psychopharmacol. 1993 Jan;7(3-4):133-6. Review.

PMID:
8468433
19.

RIMA--a new concept in the treatment of depression with moclobemide.

Amrein R, Hetzel W, Stabl M, Schmid-Burgk W.

Int Clin Psychopharmacol. 1993 Jan;7(3-4):123-32. Review.

PMID:
8468432
20.

Pharmacology of moclobemide.

Haefely W, Burkard WP, Cesura A, Colzi A, Kettler R, Lorez HP, Martin JR, Moreau JL, Richards JG, Schaffner R, et al.

Clin Neuropharmacol. 1993;16 Suppl 2:S8-18. Review.

PMID:
8313402
21.

Safety of moclobemide in clinical use.

Chen DT, Ruch R.

Clin Neuropharmacol. 1993;16 Suppl 2:S63-8. Review.

PMID:
8313399
22.

RIMA: a safe concept in the treatment of depression with moclobemide.

Amrein R, Hetzel W, Stabl M, Schmid-Burgk W.

Can J Psychiatry. 1992 Sep;37 Suppl 1:7-11. Review.

PMID:
1394030
23.

[Moclobemide (Aurorix), the first MAO-A-inhibitor: really something new?].

Nolen WA, Birkenhäger TK, Moleman P.

Ned Tijdschr Geneeskd. 1992 Aug 1;136(31):1492-6. Review. Dutch. No abstract available.

PMID:
1495565
24.

Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness.

Fitton A, Faulds D, Goa KL.

Drugs. 1992 Apr;43(4):561-96. Review. Erratum in: Drugs 1992 Sep;44(3):374. Drugs 1993 Jun;45(6):894.

PMID:
1377119
25.

Theoretical considerations and perspectives on the onset of action of moclobemide.

Gachoud JP, Mikkelsen H, Ammar S, Widlöcher D, Jouvent R.

Psychopharmacology (Berl). 1992;106 Suppl:S96-7. Review.

PMID:
1546153
26.

Biochemistry and pharmacology of moclobemide, a prototype RIMA.

Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, Richards JG, Scherschlicht R, Da Prada M.

Psychopharmacology (Berl). 1992;106 Suppl:S6-14. Review.

PMID:
1546143
27.

Behavioural toxicity of antidepressants with particular reference to moclobemide.

Hindmarch I, Kerr J.

Psychopharmacology (Berl). 1992;106 Suppl:S49-55. Review.

PMID:
1546141
28.

Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies.

Amrein R, Güntert TW, Dingemanse J, Lorscheid T, Stabl M, Schmid-Burgk W.

Psychopharmacology (Berl). 1992;106 Suppl:S24-31. Review.

PMID:
1546135
29.

Moclobemide: a range of opportunities.

Priest RG.

Psychopharmacology (Berl). 1992;106 Suppl:S140-1. Review. No abstract available.

PMID:
1546131
30.

Depression and senile dementia of the Alzheimer type: a role for moclobemide.

Chan-Palay V.

Psychopharmacology (Berl). 1992;106 Suppl:S137-9. Review.

PMID:
1546130
31.

Interaction studies with moclobemide.

Zimmer R, Gieschke R, Fischbach R, Gasic S.

Acta Psychiatr Scand Suppl. 1990;360:84-6. Review.

PMID:
2248085
32.

Hypotensive action and weak potentiation of tyramine effect by moclobemide in rats.

Da Prada M, Burkard WP.

Acta Psychiatr Scand Suppl. 1990;360:106-7. Review.

PMID:
2248060
33.

Short-lasting and reversible inhibition of monoamine oxidase-A by moclobemide.

Da Prada M, Kettler R, Keller HH, Burkard WP.

Acta Psychiatr Scand Suppl. 1990;360:103-5. Review.

PMID:
2248059
34.

Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.

Kettler R, Da Prada M, Burkard WP.

Acta Psychiatr Scand Suppl. 1990;360:101-2. Review.

PMID:
2248058
35.

From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors.

Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Saura Marti J, Muggli-Maniglio D, Wyss PC, Kyburz E, Imhof R.

J Neural Transm Suppl. 1990;29:279-92. Review.

PMID:
2193111
36.

Pre-clinical pharmacology of moclobemide. A review of published studies.

Burkard WP, Da Prada M, Keller HH, Kettler R, Haefely W.

Br J Psychiatry Suppl. 1989 Oct;(6):84-8. Review.

PMID:
2695131
37.

[Moclobemide in the treatment of depression--an overview].

Laux G.

Psychiatr Prax. 1989 Aug;16 Suppl 1:37-40. Review. German.

PMID:
2685855
38.

The effects of moclobemide on cognition.

Wesnes KA, Simpson PM, Christmas L, Anand R, McClelland GR.

J Neural Transm Suppl. 1989;28:91-102. Review.

PMID:
2677245
39.

Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states.

Stabl M, Biziére K, Schmid-Burgk W, Amrein R.

J Neural Transm Suppl. 1989;28:77-89. Review.

PMID:
2677244
40.

Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.

Da Prada M, Kettler R, Keller HH, Burkard WP, Haefely WE.

J Neural Transm Suppl. 1989;28:5-20. Review.

PMID:
2677242
41.

On tyramine, food, beverages and the reversible MAO inhibitor moclobemide.

Da Prada M, Zürcher G, Wüthrich I, Haefely WE.

J Neural Transm Suppl. 1988;26:31-56. Review.

PMID:
3283290
42.

Some in vitro effects of moclobemide and other MAO inhibitors on responses to sympathomimetic amines.

Callingham BA, Ovens RS.

J Neural Transm Suppl. 1988;26:17-29. Review.

PMID:
3283289
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk